Asset Advisors Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Asset Advisors Investment Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,740	Closed	-$643K	–	97
2021 Q4	$643K	Hold	5,740	–	–	0.06%	73
2021 Q3	$722K	Hold	5,740	–	–	0.08%	70
2021 Q2	$777K	Hold	5,740	–	–	0.09%	70
2021 Q1	$744K	Hold	5,740	–	–	0.09%	72
2020 Q4	$808K	Hold	5,740	–	–	0.1%	66
2020 Q3	$640K	Hold	5,740	–	–	0.1%	66
2020 Q2	$643K	Hold	5,740	–	–	0.1%	69
2020 Q1	$445K	Sell	5,740 -375	-6%	-$33.2K	0.08%	80
2019 Q4	$585K	Buy	6,115 +225	+4%	+$19.5K	0.09%	77
2019 Q3	$449K	Sell	5,890 -225	-4%	-$18.7K	0.07%	79
2019 Q2	$536K	Hold	6,115	–	–	0.09%	72
2019 Q1	$554K	Hold	6,115	–	–	0.1%	73
2018 Q4	$439K	Sell	6,115 -100	-2%	-$8.06K	0.09%	72
2018 Q3	$596K	Buy	+6,215	New	+$603K	0.1%	77

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Asset Advisors Investment Management's XBI Position: Q1 2022 in Review

Asset Advisors Investment Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 5,740 shares — an estimated $643K sold.

Asset Advisors Investment Management first reported a position in XBI in Q3 2018 and held it in 14 quarters. The position peaked at $808K in Q4 2020. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Asset Advisors Investment Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Asset Advisors Investment Management sold 5,740 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $643K.
Asset Advisors Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and held it in 14 quarters.
Asset Advisors Investment Management's State Street SPDR S&P Biotech ETF position peaked at $808K in Q4 2020.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Asset Advisors Investment Management's 13F filing for Q1 2022, filed 22 Apr 2022.